Early Access to Medicines Scheme (EAMS) scientific opinion: Remdesivir in the treatment of patients hospitalised with suspected or laboratory-confirmed SARS-CoV-2 infection who meet the clinical criteria

MHRA has given the first positive scientific opinion under the EAMS for use of Gilead’s remdesivir. The scientific opinion includes a public assessment report & treatment protocols for healthcare professionals, patients and pharmacovigilance system.

SPS commentary:

An accompanying alert provides information on medicine supply, access criteria, data collection and implementation.


Medicines and Healthcare products Regulatory Agency

Resource links: